Halozyme Therapeutics (HALO) Tops Q3 EPS by 31c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Total darkness, then sunset as full eclipse wows spectators in Spain
- Burry doubles down on Nebius short after stock surges 34% on earnings
Halozyme Therapeutics (HALO) PT Raised to $58 at Leerink Partners
November 1, 2024 7:21 AM EDTLeerink Partners analyst David Risinger raised the price target on Halozyme Therapeutics (NASDAQ: HALO) to $58.00 (from $56.00) while maintaining a Market Perform rating.
The analyst comments "Bottom line: We revised our model post-3Q results and bumped our DCF-derived PT from $56 to $58 (we... More
